PARSIPPANY, N.J., March 9 /PRNewswire/ -- Innovex, the commercialization unit of Quintiles Transnational Corp., today announced a recent agreement to recruit and deploy a team of 100 sales representatives to promote a leading primary care product for a global pharmaceutical company.
Innovex has used its expanded portfolio of candidate screening capabilities, including proprietary Web-based and telephone screening technologies and behavior assessment tools, to help staff this sales team with qualified and experienced representatives.
"Building quality sales forces is our core service," said Tony Yost, President, Innovex North America. "With each new team that we recruit and deploy, our array of services remains flexible to meet the exact commercialization needs of every individual customer. A strong knowledge of customer products, proven selling skills and the desire to succeed are essential qualities of every representative we place in the field."
Under the agreement, this dedicated sales force is positioned in the customer's sales territories throughout the United States.
Innovex, the commercialization unit of Quintiles Transnational Corp., is a leading commercial solutions provider that offers sales and marketing services designed to accelerate the success of pharmaceutical, biotechnology and medical device products. Since 1996, Innovex has built more than 110 sales forces, and hired more than 13,500 sales representatives to help launch more than 160 products for leading pharmaceutical companies in the United States. For more information, visit http://www.innovex.com/ .
Quintiles helps improve healthcare worldwide by providing a broad range of professional services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. Headquartered near Research Triangle Park, North Carolina, and with offices in more than 50 countries, Quintiles is a leading global pharmaceutical services organization and a member of the Fortune 1000. For more information visit the company's Web site at http://www.quintiles.com/ .
This press release contains "forward-looking statements" regarding Quintiles that involve risks and uncertainties that could cause actual results to differ materially, including without limitation the risk that the market for our products and services will not grow as we expect, our ability to efficiently distribute backlog among therapeutic business units and match demand to resources, actual operating performance, the ability to maintain large client contracts or to enter new contracts, changes in trends in the pharmaceutical industry, and the ability to operate successfully in new lines of business. Additional factors that could cause actual results to differ materially are discussed in Quintiles' recent filings with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, its Form 8-Ks, and its other periodic reports, including Form 10-Qs.
Quintiles Transnational Corp.
CONTACT: Tom Fuldner, Media Relations, +1-919-998-2091, email@example.com, or Greg Connors, Investor Relations,+1-919-998-2000, or firstname.lastname@example.org, both of Quintiles TransnationalCorp.